Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Crimean-Congo Haemorrhagic Fever Vaccine (CCHFVaccine)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2022,
Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary researc ...
Voir le projet
15
Participants partenaires
TERMINÉ
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet
43
Participants partenaires
TERMINÉ
Investigating the impact of meditation training on mental health and wellbeing in the ageing population (MEDIT-AGEING)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that lifestyle factors and meditation practice have the potent ...
Voir le projet
12
Participants partenaires
TERMINÉ
Application of omics-based strategies for improved diagnosis and treatment of endocrine hypertension (ENSAT-HT)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic hear ...
Voir le projet
13
Participants partenaires
TERMINÉ
Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinica ...
Voir le projet
17
Participants partenaires
TERMINÉ
Coordination Action in support of the sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases (JPsustaiND)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,
The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). Since 2009 JPND has been operating on a very light management structure based on a simple Terms of Reference. Through this JPND has been able to set a common Strategic Research Agenda, and to deliver its ...
Voir le projet
16
Participants partenaires
TERMINÉ
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient s ...
Voir le projet
12
Participants partenaires
TERMINÉ
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,
ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Voir le projet
7
Participants partenaires
TERMINÉ
"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" (EXALT)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Voir le projet
7
Participants partenaires
TERMINÉ
Heart OMics in AGEing (HOMAGE)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,
As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet
22
Participants partenaires
TERMINÉ
Metagenomics in Cardiometabolic Diseases (METACARDIS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,
METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ag ...
Voir le projet
18
Participants partenaires
TERMINÉ
Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis (Myasterix)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction ...
Voir le projet
6
Participants partenaires
TERMINÉ
Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,
In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre ...
Voir le projet
13
Participants partenaires
TERMINÉ
Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility (NanoAthero)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented ...
Voir le projet
17
Participants partenaires
TERMINÉ
Nanotherapeutics for antibiotic resistant emerging bacterial pathogens (NAREB)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,
Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.NAREB will address the problem of drug bioavailability inside the infected macrophages, transport ...
Voir le projet
16
Participants partenaires
TERMINÉ
Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)
Date du début: 1 mars 2011, Date de fin: 31 déc. 2017,
RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto ...
Voir le projet
10
Participants partenaires
TERMINÉ
Taking imaging into the therapeutic domain: Self-regulation of brain systems for mental disorders (BRAINTRAIN)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Our proposal is based on the idea that real-time functional neuroimaging can be used to train patients to regulate their own brain activity via neurofeedback training and thus modulate the brain networks of mental disorder, restore function, improve symptoms and promote resilience. We have brought together the core groups that have been instrumental in the development of methods for real-time func ...
Voir le projet
12
Participants partenaires
TERMINÉ
Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet
10
Participants partenaires
TERMINÉ
Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet
11
Participants partenaires
TERMINÉ
European Research Infrastructure on Highly Pathogenic Agents 2 (ERINHA2)
Date du début: 1 janv. 2016, Date de fin: 30 juin 2017,
ERINHA2 aims to complete the work carried out during the first preparatory phase (PP1) - ERINHA - in order to reach the financial, administrative and technical maturity necessary to complete the establishment of the Research Infrastructre and ensure that the operation phase can begin in 2018. ERINHA2 will therefore finalise the decision to use the status of an association and prepare the necessary ...
Voir le projet
17
Participants partenaires
TERMINÉ
Beta cell preservation via antigen-specific immunotherapy in Type 1 Diabetes: Enhanced Epidermal Antigen Delivery Systems (EE-ASI)
Date du début: 1 sept. 2012, Date de fin: 31 mai 2017,
Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems. However, less than 30% of patients can achieve target levels of glucose control with this approach even in a clinical trial setting and many patients are either unable or unwilling to make the personal commitment required. By contrast, preservation of even sma ...
Voir le projet
8
Participants partenaires
TERMINÉ
Anti-Parasitic Drug Discovery in Epigenetics (A-PARADDISE)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2017,
This proposal builds on the proven methodology developed in the SEtTReND FP7 project to develop inhibitors of schistosome HME as lead compounds for new drugs. We will employ a target-based strategy for the development of novel drug leads against schistosomiasis, leishmaniasis, Chagas disease and malaria by targeting histone modifying enzymes (HME), in particular those involved in acetylation/deace ...
Voir le projet
16
Participants partenaires
TERMINÉ
European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet
38
Participants partenaires
TERMINÉ
SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING (AGEDBRAINSYSBIO)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,
In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological principles of human aging, cognitive decline remains as one of the greatest health challenges of the old age, with nearly 50% of adults over 85 afflicted of Alzheimer’s disease. Furthermore, drug development has not performed as expected in clinical trials, at le ...
Voir le projet
15
Participants partenaires
TERMINÉ
Point-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus (PoC-HCV)
Date du début: 1 sept. 2013, Date de fin: 31 août 2016,
Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from these enabling technologies will be integrated using novel bioinformatics tools and algorithms (Qlucore) allowing for bed-side analysis. This integrated genetic-protein app ...
Voir le projet
5
Participants partenaires
TERMINÉ
Developing Innovative Outreach and Dialogue on responsible nanotechnologies in EU civil society (NANODIODE)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2016,
Stakeholder engagement and dialogue are essential to the responsible development of nanotechnologies in Europe. NANODIODE establishes an innovative, coordinated programme for outreach and dialogue throughout Europe to support the effective governance of nanotechnologies. The project integrates vital engagement activities along the innovation value chain: it combines ‘upstream’ public engagement (b ...
Voir le projet
15
Participants partenaires
TERMINÉ
Syndromic approach to Neglected Infectious Diseases (NID) at primary health care level: an international collaboration on integrated diagnostic-treatment platforms (NIDIAG)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Neglected Infectious Diseases (NID) such as trypanosomiasis, leishmaniasis, schistosomiasis and soil-transmitted helminthiasis receive less than 5% of the global investment for tropical diseases research. Clinical praxis in disease-endemic countries (DEC) is rarely evidence based and does not make use of the latest innovations in diagnostic technology. NID–related research on diagnostics is partic ...
Voir le projet
13
Participants partenaires
TERMINÉ
Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases (PreDicta)
Date du début: 1 oct. 2010, Date de fin: 31 mars 2016,
Chronic inflammatory diseases associated with allergy, including asthma and rhinitis, constitute a major and continuously growing public health concern for Europe. However, the causative factors and mechanisms converting a physiological inflammatory reaction to a chronic response triggering allergic disease remain elusive.Viral infections, particularly those caused by human rhinoviruses (RV) are t ...
Voir le projet
13
Participants partenaires
TERMINÉ
Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet
17
Participants partenaires
TERMINÉ
Stem Cells for Relevant Efficient Extended and Normalized Toxicology (SCR&TOX)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely ...
Voir le projet
16
Participants partenaires
TERMINÉ
HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three ...
Voir le projet
13
Participants partenaires
TERMINÉ
Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2015,
The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet
16
Participants partenaires
TERMINÉ
European Network of Knowledge Transfer in Health (ENTENTE)
Date du début: 1 sept. 2012, Date de fin: 31 août 2015,
The objective the ENTENTE project is to reinforce knowledge transfer (KT) offices in universities, public research organisations, hospitals and to promote industry academia transnational collaboration in the health sector. This will be achieved through seven sub-objectives:1-The development of a web platform for shared learning and networking including best practices, video interviews, networking ...
Voir le projet
7
Participants partenaires
TERMINÉ
Chips for Life (C4L)
Date du début: 1 janv. 2012, Date de fin: 30 juin 2015,
Respiratory tract infections (RTIs) are a huge burden in terms of mortality and morbidity worldwide. To improve the management of the bacterial infections of the respiratory tract, the institution of an appropriate antimicrobial therapy as soon as possible has also been shown to be a key element for reducing morbidity and mortality. The aim of our project is to develop a panel of dedicated rapid d ...
Voir le projet
8
Participants partenaires
TERMINÉ
Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance (OVER-MYR)
Date du début: 1 janv. 2012, Date de fin: 30 juin 2015,
Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Voir le projet
11
Participants partenaires
TERMINÉ
Mechanisms of the Development of ALLergy (MEDALL)
Date du début: 1 déc. 2010, Date de fin: 31 mai 2015,
Causes explaining the epidemic of IgE-associated (allergic) diseases are unclear. MeDALL (Mechanisms of the Development of Allergy) aims at generating novel knowledge on mechanisms of allergy initiation, in particular in childhood. To understand how a complex network of genetic and environmental factors leads to complex allergic phenotypes, a novel stepwise, large and integrative translational app ...
Voir le projet
24
Participants partenaires
TERMINÉ
Crimean Congo Hemorrhagic Fever; Modern Approaches to Diagnostics, Surveillance, Prevention, Therapy and Preparedness (CCH Fever)
Date du début: 1 oct. 2010, Date de fin: 31 mars 2015,
Over the last years, large outbreaks of Crimean Congo Hemorrhagic fever virus (CCHFV) in several European countries and neighbouring areas are on the rise. This disease poses a great threat to public health due to its high mortality rate, modes of transmission and geographical distribution. Climate changes and observation of the CCHFV vector in central Europe alarm the European community as we can ...
Voir le projet
18
Participants partenaires
TERMINÉ
The role of intestinal microflora in non-alcoholic fatty liver disease (NAFLD) (FLORINASH)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,
As worldwide metabolic disease pandemics rise relentlessly with their concomitant clinical complications such as non alcoholic fatty liver disease, FLORINASH proposes an innovative research concept to address the role of intestinal microfloral activity in the pathogenesis of NAFLD. Firstly, to discover novel metabolic markers for the differential diagnosis and prediction of patient risk. Secondly, ...
Voir le projet
6
Participants partenaires
TERMINÉ
Innovative strategies to generate human hepatocytes for treatment of metabolic Liver diseases: Tools for personalized cell therapy (InnovaLiv)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2014,
Transplantation of donor hepatocytes has become an alternative to liver transplantation for the treatment of liver diseases. However, in addition to the complication imposed by severe shortage of donor livers, adult hepatocytes cannot be expanded in vitro. Autologous transplantation of genetically corrected hepatocytes represents another strategy as it circumvents the need for immunosuppression bu ...
Voir le projet
7
Participants partenaires
TERMINÉ
Health Competence in Europe (HEALTHCOMPETENCE)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2014,
The results generated through EC funded projects represent a considerable part of health research in Europe. Access to high-quality information on these research activities & results is therefore critical for planning & strategic decision making, and hence strengthening the involved stakeholders' innovation capabilities. The objective of HealthCompetence is to ensure an adequate access to this inf ...
Voir le projet